Melinta Therapeutics is a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat serious bacterial infections. Operating in the healthcare and pharmaceutical markets, Melinta serves hospitals, healthcare providers, and patients who are in need of effective treatments for resistant bacterial infections. The company's business model revolves around research and development (R&D) of new antibiotics, followed by the commercialization of these drugs through sales and partnerships. Revenue is generated primarily through the sale of its antibiotic products and licensing agreements. Melinta's mission is to address the continually evolving threat of bacterial infections by providing innovative solutions that meet the needs of patients and healthcare providers. The company emphasizes collaboration, inclusivity, and agility in its operations to achieve ambitious goals and make a significant impact in the field of infectious diseases.

Keywords: antibiotics, bacterial infections, biopharmaceutical, healthcare, pharmaceutical, hospitals, R&D, commercialization, licensing, infectious diseases.